Early Diagnosis of JIA
Juvenile Idiopathic Arthritis (JIA) is a serious childhood autoimmune inflammatory disease, which can have a devastating impact on the day-to-day lives of those affected and their families.
After the diagnosis of Thomas, the son of ANCON Medical’s CEO, Wesley Baker, in 2017, ANCON has proudly offered support for JIA-at-NRAS, a part of the National Rheumatoid Arthritis Society, and its aim is to support children, young people and adults with JIA to live life to the full. Since his diagnosis, Thomas has undergone several treatments at Kent and Canterbury Hospital and Great Ormond Street Children’s Hospital in London and is courageously fighting against painful symptoms each day.
JIA is a chronic autoimmune disease, where your immune system gets confused and attacks healthy joint tissue, causing inflammation. The literal translation of the disease is:
Juvenile: patient aged 16 or under when the problem started,
Idiopathic: of unknown cause,
Arthritis: inflammation inside the joint seen by swelling, warmth and reduced movement.
There are an estimated 12,000 children and young people living with JIA in UK, representing 1 child in every 1,000 under the age of 16, with 1,000 – 1,500 new cases each year.
Early diagnosis is key to limiting the progression of this painful and potentially debilitating disease and this is precisely the kind of condition where ANCON Medical’s advanced disease screening technology can be life changing. Non-invasive, simple to use, and affordable, the ANCON’s Nanoparticle Biomarker Tagging (NBT) technology can detect the presence of disease by measuring exhaled breath for signs of the disease.
The technology works by detecting breath specific “biomarkers,” which are DNA-protein controlled volatile organic compound (VOC) metabolites specific to diseases. Researchers have discovered biomarkers for more than 400 diseases, including lung, bowel and other cancers.
By using machine learning software in association with the NBT technology the device can hunt for these specific molecules, so that the disease can be diagnosed early, thereby increasing treatment options and survival probability. No technology on the market is as highly sensitive at detecting biomarkers as NBT, which can detect the fingerprints of the disease at concentrations as low as one ion in 10,000 cubic centimeters, giving the device a sensitivity that could be measured down to a single molecule.
“The NBT device is very versatile and promises to change the lives of children as yet undiagnosed with this painful disease in a non-invasive and much less intimidating way than current testing procedures. Although unfortunately too late for Thomas’s JIA diagnosis, it can also be used to screen for diseases such as cancer and potentially be reassigned to test for a range of other diseases when needed,” says Wesley Baker, who is a member of the Royal Society of Medicine.